keyword
MENU ▼
Read by QxMD icon Read
search

Sunitinib

keyword
https://www.readbyqxmd.com/read/28212559/the-selective-mek1-inhibitor-selumetinib-enhances-the-antitumor-activity-of-everolimus-against-renal-cell-carcinoma-in-vitro-and-in-vivo
#1
Yun Zou, Jianfeng Wang, Xuejiao Leng, Jiwei Huang, Wei Xue, Jin Zhang, Yiran Huang
Renal cell carcinoma (RCC) is a urologic malignant cancer and often diagnosed at an advanced stage, which results in high mortality. Targeted therapy may improve the quality of life and survival of patients who are not suitable for nephrectomy. Everolimus, an mTOR inhibitor, is currently used as sequential or second-line therapy for RCC refractory to Sunitinib or sorafenib. However, its efficiency is palliative. In this study, we evaluated whether the antitumor activity of everolimus against RCC is enhanced by Selumetinib, a selective MEK1 inhibitor...
February 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/28208511/re-first-line-sunitinib-versus-pazopanib-in-metastatic-renal-cell-carcinoma-results-from-the-international-metastatic-renal-cell-carcinoma-database-consortium
#2
https://www.readbyqxmd.com/read/28205224/muc13-overexpression-in-renal-cell-carcinoma-plays-a-central-role-in-tumour-progression-and-drug-resistance
#3
Yonghua Sheng, Choa Ping Ng, Rohan Lourie, Esha T Shah, Yaowu He, Kuan Yau Wong, Inge Seim, Iulia Oancea, Christudas Morais, Penny L Jeffery, John Hooper, Glenda C Gobe, Michael A McGuckin
Metastatic renal cell carcinoma is a largely incurable disease, and existing treatments targeting angiogenesis and tyrosine kinase receptors are only partially effective. Here we reveal that MUC13, a cell surface mucin glycoprotein, is aberrantly expressed by most renal cell carcinomas, with increasing expression positively correlating with tumor grade. Importantly, we demonstrated that high MUC13 expression was a statistically significant independent predictor of poor survival in two independent cohorts, particularly in stage 1 cancers...
February 16, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28199818/cabozantinib-versus-sunitinib-as-initial-targeted-therapy-for-patients-with-metastatic-renal-cell-carcinoma-of-poor-or-intermediate-risk-the-alliance-a031203-cabosun-trial
#4
Toni K Choueiri, Susan Halabi, Ben L Sanford, Olwen Hahn, M Dror Michaelson, Meghara K Walsh, Darren R Feldman, Thomas Olencki, Joel Picus, Eric J Small, Shaker Dakhil, Daniel J George, Michael J Morris
Purpose Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell carcinoma (mRCC). This randomized phase II multicenter trial evaluated cabozantinib compared with sunitinib as first-line therapy in patients with mRCC. Patients and Methods Eligible patients had untreated clear cell mRCC and Eastern Cooperative Oncology Group performance status of 0 to 2 and were intermediate or poor risk per International Metastatic Renal Cell Carcinoma Database Consortium criteria...
February 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28197036/induction-of-trismus-by-sunitinib-and-pazopanib-in-metastatic-renal-cell-carcinoma
#5
Ridhima Iyer, Bruce Montgomery, Hardev S Pandha
Tyrosine kinase inhibitors sunitinib and pazopanib are used as first-line agents in the treatment of metastatic renal cell carcinoma. Treatment-related toxicities have been described with both these drugs. This report describes a patient with metastatic renal carcinoma who developed trismus while being treated with these agents and is, to the best of our knowledge, the first such case to be reported.
January 2017: Indian Journal of Urology: IJU: Journal of the Urological Society of India
https://www.readbyqxmd.com/read/28196874/prospective-evaluation-of-sunitinib-induced-cardiotoxicity-in-patients-with-metastatic-renal-cell-carcinoma
#6
Vivek Narayan, Stephen M Keefe, Naomi Haas, Le Wang, Igor Puzanov, Mary E Putt, Anna Catino, James Fang, Neeraj Agarwal, David Hyman, Amanda M Smith, Brian S Finkelman, Hari K Narayan, Steven Ewer, Chantal ElAmm, Daniel J Lenihan, Bonnie Ky
PURPOSE: To prospectively evaluate cardiotoxicity risk with sunitinib in metastatic renal cell carcinoma (mRCC) routine clinical practice using comprehensive echocardiography and biomarker phenotyping. PATIENTS AND METHODS: In a multi-center prospective study of 90 mRCC patients, echocardiography and biomarkers of cardiovascular injury and stress were quantified at baseline, 3.5, 15, and 33 weeks following sunitinib initiation. These "on-drug" visits corresponded to cycles 1, 3, and 6, respectively...
February 14, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28188447/a-prospective-observational-study-on-the-evaluation-of-everolimus-related-adverse-events-in-metastatic-renal-cell-carcinoma-after-first-line-anti-vascular-endothelial-growth-factor-therapy-the-afinite-study-in-france
#7
Florence Joly, Jean-Christophe Eymard, Laurence Albiges, Thierry Nguyen, Aline Guillot, Frederic Rolland, Dominique Spaeth, Brigitte Laguerre, Thierry Lebret, Nadia Kelkouli, Khemaies Slimane, Alain Ravaud
PURPOSE: The objective of the study was to describe the occurrence of stomatitis and noninfectious lung disease in patients with metastatic renal cell carcinoma (mRCC) treated with second-line everolimus in a real-world setting. METHODS: This multicenter, prospective, observational study was conducted in France by physicians with experience of treatment of patients with mRCC. Patients aged ≥18 years who received everolimus after first-line antivascular endothelial growth factor (VEGF) therapy were included in the study...
February 10, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28184014/autophagy-inhibition-enhances-sunitinib-efficacy-in-clear-cell-ovarian-carcinoma
#8
Lindsay DeVorkin, Matthew Hattersley, Paul Kim, Jenna Ries, Jaeline Spowart, Michael S Anglesio, Samuel M Levi, David G Huntsman, Ravi K Amaravadi, Jeffrey D Winkler, Anna V Tinker, Julian J Lum
Clear cell ovarian carcinoma (CCOC) is an aggressive form of epithelial ovarian cancer that exhibits low response rates to systemic therapy and poor patient outcomes. Multiple studies in CCOC have revealed expression profiles consistent with increased hypoxia, and our previous data suggest that hypoxia is correlated with increased autophagy in CCOC. Hypoxia-induced autophagy is a key factor promoting tumor cell survival and resistance to therapy. Recent clinical trials with the molecular-targeted receptor tyrosine kinase (RTK) inhibitor sunitinib have demonstrated limited activity...
February 9, 2017: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/28183292/case-report-rapid-and-durable-response-to-pdgfr-targeted-therapy-in-a-child-with-refractory-multiple-infantile-myofibromatosis-and-a-heterozygous-germline-mutation-of-the-pdgfrb-gene
#9
Peter Mudry, Ondrej Slaby, Jakub Neradil, Jana Soukalova, Kristyna Melicharkova, Ondrej Rohleder, Marta Jezova, Anna Seehofnerova, Elleni Michu, Renata Veselska, Jaroslav Sterba
BACKGROUND: Infantile myofibromatosis belongs to a family of soft tissue tumors. The majority of these tumors have benign behavior but resistant and malignant courses are known, namely in tumors with visceral involvement. The standard of care is surgical resection. Observations suggest that low dose chemotherapy is beneficial. The treatment of resistant or relapsed patients with multifocal disease remains challenging. Patients that harbor an actionable mutation in the kinase domain are potential subjects for targeted tyrosine kinase inhibitor therapy...
February 10, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28181828/synthesis-of-sericin-based-conjugates-by-click-chemistry-enhancement-of-sunitinib-bioavailability-and-cell-membrane-permeation
#10
Luca Scrivano, Domenico Iacopetta, Maria Stefania Sinicropi, Carmela Saturnino, Pasquale Longo, Ortensia Ilaria Parisi, Francesco Puoci
Sericin is a natural protein that has been used in biomedical and pharmaceutical fields as raw material for polypeptide-based drug delivery systems (DDSs). In this paper, it has been employed as pharmaceutical biopolymer for the production of sunitinib-polypeptide conjugate. The synthesis has been carried out by simple click reaction in water, using the redox couple l-ascorbic acid/hydrogen peroxide as a free radical grafting initiator. The bioconjugate molecular weight (50 kDa < Mw < 75 kDa) was obtained by SDS-PAGE, while the spectroscopic characteristics have been studied in order to reveal the presence of grafted sunitinib...
November 2017: Drug Delivery
https://www.readbyqxmd.com/read/28178674/plasma-cytokine-and-angiogenic-factors-associated-with-prognosis-and-therapeutic-response-to-sunitinib-vs-everolimus-in-advanced-non-clear-cell-renal-cell-carcinoma
#11
Pavlos Msaouel, Amado J Zurita, Shixia Huang, Eric Jonasch, Nizar M Tannir
No biomarkers are available to predict relative clinical benefit from targeted therapies in patients with non-clear cell renal cell carcinoma (nccRCC). To identify candidate predictive markers, we investigated a set of cytokines and angiogenic factors (CAFs) in previously untreated patients with nccRCC participating in the phase II ESPN trial comparing first-line sunitinib to everolimus. Pre-treatment concentrations of 30 CAFs were measured in plasma from 37 patients treated with everolimus (n=16) or sunitinib (n=21), and associated with progression-free (PFS) and overall survival (OS) after adjusting for potential confounders...
February 2, 2017: Oncotarget
https://www.readbyqxmd.com/read/28178630/combination-of-sl327-and-sunitinib-malate-leads-to-an-additive-anti-cancer-effect-in-doxorubicin-resistant-thyroid-carcinoma-cells
#12
Wei Wang, Jin Zhou, Lujie Zhao, Shulin Chen
BACKGROUND: Receptor tyrosine kinases (RTKs) play crucial roles in numerous cancer cell processes including cell survival, proliferation, and migration. MEK1/2 MAPK kinases are very important for cancer survival and development. Anaplastic thyroid carcinoma (ATC) is a deadly type of thyroid cancer and there are no very effective systemic treatment strategies for ATC so far. Also, ATC can easily become resistant to therapy of traditional therapeutic drugs for ATC, such as doxorubicin. Drug combination treatment could be a promising therapeutic strategy for ATC, especially for drug resistant ATC...
February 5, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28178124/anaplastic-thyroid-carcinoma-and-foscarnet-use-in-a-multitarget-treatment-documented-by-18f-fdg-pet-ct-a-case-report
#13
Elisa Giannetta, Andrea M Isidori, Cosimo Durante, Cira Di Gioia, Flavia Longo, Vincenzo Tombolini, Nadia Bulzonetti, Chiara Graziadio, Riccardo Pofi, Daniele Gianfrilli, Antonella Verrienti, Raffaella Carletti, Sebastiano Filetti, Andrea Lenzi, Alberto Baroli
RATIONALE: The case reported the rapid remission of disease recurrence achieved adding foscarnet, a DNA polymerase inhibitor that interacts with fibroblast growth factor 2, to low molecular weight heparin and sunitinib for the first time in a patient with an anaplastic thyroid cancer (ATC). PATIENT CONCERNS: A 65-year-old woman with a multinodular goiter referred for a rapid enlargement of a nodule. Histological examination revealed an ATC with a little area of papillary thyroid cancer (PTC)...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28177066/sunitinib-in-pancreatic-neuroendocrine-tumors-updated-progression-free-survival-and-final-overall-survival-from-a-phase-iii-randomized-study
#14
S Faivre, P Niccoli, D Castellano, J W Valle, P Hammel, J-L Raoul, A Vinik, E Van Cutsem, Y-J Bang, S-H Lee, I Borbath, C Lombard-Bohas, P Metrakos, D Smith, J-S Chen, P Ruszniewski, J-F Seitz, S Patyna, D R Lu, K J Ishak, E Raymond
No abstract text is available yet for this article.
November 10, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28167571/pharmacoepidemiology-of-clinically-relevant-hypothyroidism-and-hypertension-from-sunitinib-and-sorafenib
#15
Christine M Walko, Ronald E Aubert, Ninh M La-Beck, Gosia Clore, Vivian Herrera, Helen Kourlas, Robert S Epstein, Howard L McLeod
BACKGROUND: Thyroid dysfunction and hypertension (HTN) have been sporadically reported with sunitinib (SUN) and sorafenib (SOR). Determination of the side effect incidence will enhance monitoring and management recommendations. METHODS: An observational cohort study was performed using deidentified pharmacy claims data from a 3-year period to evaluate patients prescribed SUN, SOR, or capecitabine (CAP; comparison group). The primary outcome was time to first prescription for thyroid replacement or HTN treatment...
February 6, 2017: Oncologist
https://www.readbyqxmd.com/read/28167241/the-effect-of-sunitinib-treatment-in-human-melanoma-xenografts-associations-with-angiogenic-profiles
#16
Jon-Vidar Gaustad, Trude G Simonsen, Lise Mari K Andersen, Einar K Rofstad
The effect of antiangiogenic agents targeting the vascular endothelial growth factor A (VEGF-A) pathway has been reported to vary substantially in preclinical studies. The purpose of this study was to investigate the effect of sunitinib treatment on tumor vasculature and oxygenation in melanoma xenografts with different angiogenic profiles. A-07, U-25, D-12, or R-18 melanoma xenografts were grown in dorsal window chambers and given daily treatments of sunitinib (40 mg/kg) or vehicle. Morphologic parameters of tumor vascular networks were assessed from high-resolution transillumination images, and tumor blood supply times (BSTs) were assessed from first-pass imaging movies...
February 2, 2017: Translational Oncology
https://www.readbyqxmd.com/read/28163004/intermittent-sunitinib-for-metastatic-renal-cell-carcinoma
#17
Priya Venkatesan
No abstract text is available yet for this article.
February 2, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28161554/maintenance-sunitinib-following-initial-platinum-based-combination-chemotherapy-in-advanced-stage-iiib-iv-non-small-cell-lung-cancer-a-randomized-double-blind-placebo-controlled-phase-iii-study-calgb-30607-alliance
#18
Maria Q Baggstrom, Mark A Socinski, Xiaofei F Wang, Lin Gu, Thomas E Stinchcombe, Martin J Edelman, Sherman Baker, Josephine Feliciano, Paul Novotny, Olwen Hahn, Jeffrey A Crawford, Everett E Vokes
INTRODUCTION: To evaluate efficacy of maintenance sunitinib after first-line chemotherapy for stage IIIB/IV non-small cell lung cancer (NSCLC). METHODS: Cancer and Leukemia Group B (CALGB) 30607 trial was a randomized, double-blind, placebo-controlled, phase III study that enrolled patients without progression after four cycles of first-line platinum-based doublet chemotherapy with or without bevacizumab. Bevacizumab was only allowed during the four cycles of chemotherapy...
February 1, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28159495/phase-2-trial-of-sunitinib-and-gemcitabine-in-patients-with-sarcomatoid-and-or-poor-risk-metastatic-renal-cell-carcinoma-michaelson-md-mckay-rr-werner-l-atkins-mb-van-allen-em-olivier-km-song-j-signoretti-s-mcdermott-df-choueiri-tk-cancer-2015-oct-1-121-19
#19
Raman Jay, R R McKay, L Werner, M B Atkins, E M Van Allen, K M Olivier, J Song, S Signoretti, D F McDermott, T K Choueiri
BACKGROUND: Sarcomatoid renal cell carcinoma (RCC) is associated with an aggressive biology and a poor prognosis. Poor-risk RCC is defined by clinical prognostic factors and demonstrates similarly aggressive behavior. No standard treatment exists for patients with sarcomatoid RCC, and treatment options for patients with poor-risk disease are of limited benefit. The objective of this study was to investigate the efficacy of antiangiogenic therapy in combination with cytotoxic chemotherapy in clinically aggressive RCC...
January 31, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28156651/oams-at-the-end-the-end-of-the-beginning-or-the-beginning-of-the-end
#20
Barbara Marie Galligan, Chintan Shah, Iris Chen Zhao, Brian Paciotti, Nathan Fairman, Quy Tran
: 229 Background: In 2001, after three months of review, the FDA approved the oral anticancer agent imatinib, making it the fastest approval in FDA history. Since then, the FDA has approved over 40 oral anti-cancer medications (OAMs) and the number continues to rise, transforming cancer care, improving survival in specific cancers and providing new hope. However, the rapid development of OAMs has produced uncertainty over the best use of these new medications, particularly at the end of life...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
21148
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"